Pruritus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pruritus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Difelikefalin for Adolescents with Itching Due to Chronic Kidney Disease on Hemodialysis https://clinicaltrials.eu/trial/study-on-the-safety-of-difelikefalin-for-adolescents-with-itching-due-to-chronic-kidney-disease-on-hemodialysis/ Wed, 29 Apr 2026 15:04:17 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-difelikefalin-for-adolescents-with-itching-due-to-chronic-kidney-disease-on-hemodialysis/ This clinical trial is focused on studying the safety of a medication called difelikefalin in adolescents aged 12 to 17 years who are undergoing hemodialysis due to chronic kidney disease and are experiencing moderate-to-severe pruritus, which is a condition characterized by severe itching. The medication, known by its brand name Kapruvia, is administered as a solution for injection. The purpose of the study is to evaluate how safe this treatment is for young patients with these conditions.

Participants in the study will receive difelikefalin through an intravenous injection, which means the medication is delivered directly into a vein. The study will monitor the participants over a period to observe any side effects and to measure the levels of the medication in their blood. This will help determine how well the medication is tolerated by the body and how it behaves in the bloodstream.

The study is designed to ensure that the medication is safe for use in this specific group of patients. By participating, researchers aim to gather important information that could lead to better treatment options for adolescents suffering from itching related to long-term kidney disease. The study will continue until the estimated end date in 2029, allowing ample time to collect and analyze the data.

]]> Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-dupilumab-for-adults-with-chronic-itch-of-unknown-cause/ Wed, 29 Apr 2026 14:56:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-dupilumab-for-adults-with-chronic-itch-of-unknown-cause/ This clinical trial is focused on studying a condition known as chronic pruritus of unknown origin (CPUO), which is a persistent itch without a known cause. The trial aims to evaluate the effectiveness and safety of a medication called dupilumab, which is administered as a solution for injection. The study will also involve a comparison with a placebo to assess the true effects of the medication.

The purpose of the study is to determine how well dupilumab can reduce the sensation of itch in adults suffering from CPUO. Participants in the study will receive either the medication or a placebo and will be monitored over a period of time to observe any changes in their symptoms. The study will also include the use of other medications like fexofenadine and loratadine, which are commonly used antihistamines, to see how they interact with the treatment.

Throughout the study, participants will be asked to report on their itch levels and any changes they experience. The trial will last for several weeks, with regular check-ins to track progress and ensure safety. The ultimate goal is to find a more effective way to manage and relieve the symptoms of CPUO, improving the quality of life for those affected by this challenging condition.

]]> Study on the Effectiveness and Safety of Difelikefalin for Adults with Moderate-to-Severe Itching from Notalgia Paresthetica https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-difelikefalin-for-adults-with-moderate-to-severe-itching-from-notalgia-paresthetica/ Wed, 29 Apr 2026 14:26:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-difelikefalin-for-adults-with-moderate-to-severe-itching-from-notalgia-paresthetica/ This clinical trial is focused on studying a condition called Notalgia Paresthetica, which causes moderate to severe itching in adults. The study will investigate the effectiveness and safety of a medication called Difelikefalin, which is taken orally in the form of a tablet. Difelikefalin works as a kappa-opioid receptor (KOR) agonist, which means it interacts with specific receptors in the body to help reduce itching sensations.

The purpose of the study is to evaluate how well Difelikefalin can reduce the intensity of itching in patients with Notalgia Paresthetica. The study is divided into two parts. In the first part, three different doses of Difelikefalin will be compared to a placebo to determine which dose is most effective. In the second part, the selected dose will be further tested to see how well it reduces itching over an 8-week period. Participants will take the medication daily, and their progress will be monitored throughout the study.

Participants will be assessed on various factors, including the improvement in their itching symptoms and any changes in skin sensations like burning or tingling. The study will also monitor any side effects that may occur during and after the treatment period. The goal is to find a safe and effective dose of Difelikefalin that can help alleviate the discomfort caused by Notalgia Paresthetica.

]]>